There are 413 resources available
195P - Impact of an interactive eHealth system for patient reported outcomes on safety in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
Presenter: Nadia Harbeck
Session: Poster viewing and lunch
196P - Efficacy and safety of first-line (1L) ribociclib (RIB) + letrozole (LET) in patients (pts) with de novo metastatic disease and late recurrence from (neo)adjuvant therapy (tx) in MONALEESA (ML)-2
Presenter: Patrick Neven
Session: Poster viewing and lunch
197P - ATREZZO TRIAL (SOLTI-1907) A Phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC): interim analysis
Presenter: Tomas Pascual
Session: Poster viewing and lunch
198P - Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the Phase 3 ASCENT study
Presenter: Evandro de Azambuja
Session: Poster viewing and lunch
199P - Correlation of circulating tumor DNA (ctDNA) or Thymidine Kinase activity (TKa) Dynamic Patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2) - advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial
Presenter: Grazia Arpino
Session: Poster viewing and lunch
200P - OlympiAD: exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)
Presenter: Elzbieta Senkus-Konefka
Session: Poster viewing and lunch
201P - Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase 2 results
Presenter: Lasika Seneviratne
Session: Poster viewing and lunch
203P - Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: subgroup analysis from phase 3b LUCY trial
Presenter: Karen Gelmon
Session: Poster viewing and lunch
204P - Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment naïve patients
Presenter: Hope Rugo
Session: Poster viewing and lunch